Multiple actions of NMS-P715, the monopolar spindle 1 (MPS1) mitotic checkpoint inhibitor in liver fluke-associated cholangiocarcinoma cells

Cancer testis antigens: Emerging therapeutic targets leveraging genomic instability in cancer

“… 103 , 104 , 105 As such, Mps1 inhibition selectively reduces cancer cell proliferation and increases cancer cell aneuploidy and cell death as a result of mitotic checkpoint override, chromosomal misalignment, destabilization of kinetochores and mitotic checkpoint complexes, accumulation of irreparable DNA damage and polyploidy. 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 Mps1 expression has been observed in multiple myeloma, osteosarcoma, hepatocellular carcinoma, neuroblastoma, glioma and glioblastoma, prostate cancer, colon cancer, lung cancer, mesothelioma, pancreatic cancer, and has been associated with poor prognosis in multiple cancers. In contrast, high expression of Mps1 in triple negative breast tumors was found to correlate with a better prognosis, however, the mechanisms driving this phenotype remain unexplored.…”